Results 11 to 20 of about 82,161 (336)

Sirolimus in the treatment of kaposiform lymphangiomatosis [PDF]

Orphanet Journal of Rare Diseases, 2021
Background Kaposiform lymphangiomatosis (KLA), which is a new subtype of generalized lymphatic anomaly, is a rare disease with a poor prognosis. Currently, there is no standard treatment due to the poor understanding of KLA.
Jiangyuan Zhou, Kaiying Yang, Siyuan Chen, Yi Ji   +3 more
semanticscholar   +5 more sources

Sirolimus-tacrolimus combination immunosuppression [PDF]

The Lancet, 2000
A series of 32 recipients of liver, kidney, or pancreas transplants who were treated with sirolimus and low-dose tacrolimus experienced a low rate of rejection and excellent graft function without drug-related toxic effects.
Vivian C. McAlister, Zu‐Hua Gao, Kevork Peltekian, Javier Domingues, Kamrar Mahalati, Allan S. MacDonald   +5 more
openalex   +8 more sources

Sirolimus induced phosphaturia is not caused by inhibition of renal apical sodium phosphate cotransporters. [PDF]

PLoS ONE, 2012
The vast majority of glomerular filtrated phosphate is reabsorbed in the proximal tubule. Posttransplant phosphaturia is common and aggravated by sirolimus immunosuppression. The cause of sirolimus induced phosphaturia however remains elusive.
Maria Haller, Stefan Amatschek, Julia Wilflingseder, Alexander Kainz, Bernd Bielesz, Ivana Pavik, Andreas Serra, Nilufar Mohebbi, Jürg Biber, Carsten A Wagner, Rainer Oberbauer   +10 more
doaj   +1 more source

Sirolimus versus tacrolimus for systemic lupus erythematosus treatment: results from a real-world CSTAR cohort study

Lupus Science and Medicine, 2022
Objective The effectiveness and safety of sirolimus for SLE treatment have been shown in some uncontrolled studies. However, a comparison of sirolimus with other classic immunosuppressants has not been reported.
Xiaofeng Zeng, Qian Wang, Jiuliang Zhao, Xinping Tian, Hongbin Li, Mengtao Li, Yan Zhao, Hui Luo, Yanhong Wang, Xiaofeng Li, Pingting Yang, Xinwang Duan, Yongfei Fang, Hongfeng Zhang, Liying Peng, Chanyuan Wu   +15 more
doaj   +1 more source

nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors

Journal of Clinical Oncology, 2021
PURPOSE Malignant perivascular epithelioid cell tumor (PEComa) is a rare aggressive sarcoma, with no approved treatment. To our knowledge, this phase II, single-arm, registration trial is the first prospective clinical trial in this disease ...
A. Wagner, V. Ravi, R. Riedel, K. Ganjoo, B. V. Van Tine, R. Chugh, L. Cranmer, E. Gordon, J. Hornick, H. Du, B. Grigorian, A. Schmid, S. Hou, K. Harris, D. Kwiatkowski, N. Desai, M. Dickson   +16 more
semanticscholar   +1 more source

Interactions Between Sirolimus and Anti-Inflammatory Drugs: Competitive Binding for Human Serum Albumin [PDF]

Advanced Pharmaceutical Bulletin, 2016
Purpose: The aim of the present study was investigating the effects of three anti-inflammatory drugs, on Sirolimus protein biding. The binding site of Sirolimus on human serum albumin (HSA) was also determined.
Arash Khodaei, Soheila Bolandnazar, Hadi Valizadeh, Leila Hasani, Parvin Zakeri-Milani   +4 more
doaj   +1 more source

Sirolimus (Rapamycin) for Slow-Flow Malformations in Children: The Observational-Phase Randomized Clinical PERFORMUS Trial.

JAMA dermatology, 2021
Importance Sirolimus is increasingly being used to treat various vascular anomalies, although evidence of its efficacy is lacking. Objective To assess the efficacy and safety of sirolimus for children with slow-flow vascular malformations to better ...
A. Maruani, E. Tavernier, O. Boccara, J. Mazereeuw-Hautier, S. Leducq, D. Bessis, L. Guibaud, Pierre Vabres, V. Carmignac, S. Mallet, S. Barbarot, C. Chiaverini, C. Droitcourt, A. Bursztejn, C. Lengellé, J. Woillard, D. Herbreteau, A. Le Touze, A. Joly, C. Léauté-Labrèze, J. Powell, H. Bourgoin, V. Gissot, B. Giraudeau, B. Morel   +24 more
semanticscholar   +1 more source

Indications and Limitations of Sirolimus in the Treatment of Vascular Anomalies—Insights From a Retrospective Case Series

Frontiers in Pediatrics, 2022
BackgroundDespite recent developments, the role of sirolimus in the heterogeneous spectrum of vascular anomalies is yet to be defined, in terms of indication, dosage, and therapy duration, recognizing both its potential and limitations.MethodsWe ...
Anna Karastaneva, Paolo Gasparella, Sebastian Tschauner, Roman Crazzolara, Gabriele Kropshofer, Manfred Modl, Andreas Pfleger, Ante Burmas, Mirjam Pocivalnik, Raphael Ulreich, Werner Zenz, Wolfgang Schwinger, Besiana P. Beqo, Besiana P. Beqo, Christian Urban, Emir Q. Haxhija, Herwig Lackner, Martin Benesch   +17 more
doaj   +1 more source

A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors

Clinical Cancer Research, 2021
Purpose: To evaluate the safety and tolerability in phase I first-in-human combination therapy with pexidartinib, an inhibitor of colony-stimulating factor-1 receptor, and sirolimus, an mTOR inhibitor, to target tumor-associated macrophage (TAM ...
G. Manji, B. V. Van Tine, Shing M. Lee, A. Raufi, I. Pellicciotta, A. Hirbe, J. Pradhan, Andrew X. Chen, R. Rabadán, G. Schwartz   +9 more
semanticscholar   +1 more source

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy [PDF]

, 2016
Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum tolerated dose (MTD), recommended phase II ...
et al,, Park, Haeseong
core   +5 more sources